Blockchain Registration Transaction Record

Silo Pharma Reveals Positive Preclinical Results for Ketamine Implant Targeting Fibromyalgia

Silo Pharma announces favorable preclinical results for SP-26, an extended-release ketamine implant for fibromyalgia treatment. The study in minipigs showed safety, tolerability, and sustained ketamine release, highlighting SP-26 as a potential next-generation pain therapy with abuse-deterrent properties.

This news matters as it introduces a potential breakthrough in chronic pain management with the development of an abuse-deterrent ketamine implant. The success of SP-26 in preclinical studies signifies a promising advancement towards providing patients with an effective and safe alternative to traditional pain medications, addressing the urgent need for innovative therapies in the field of fibromyalgia treatment.